Photo from wikipedia
The aim of this study was to investigate the pharmacokinetic, pharmacodynamic and safety profile of the glucagon‐like peptide‐1 receptor agonist, lixisenatide, for the treatment of type 2 diabetes (T2D) in… Click to show full abstract
The aim of this study was to investigate the pharmacokinetic, pharmacodynamic and safety profile of the glucagon‐like peptide‐1 receptor agonist, lixisenatide, for the treatment of type 2 diabetes (T2D) in pediatric individuals.
Keywords:
safety;
pharmacokinetics pharmacodynamics;
diabetes study;
pharmacodynamics safety;
type diabetes;
study pharmacokinetics
Journal Title: Pediatric Diabetes
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Pediatric Diabetes
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!